טוען...

The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer

Breast cancer is the most prevalent cancer in women worldwide. About 15-20% of all breast cancers do not express estrogen receptor, progesterone receptor or HER2 receptor and hence are collectively classified as triple negative breast cancer (TNBC). These tumors are often relatively aggressive when...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncotarget
Main Authors: Wu, Xinyan, Saddiq, Muhammad Zahari, Renuse, Santosh, Kelkar, Dhanashree S, Barbhuiya, Mustafa A, Rojas, Pamela L, Stearns, Vered, Gabrielson, Edward, Malla, Pavani, Sukumar, Saraswati, Mahajan, Nupam P, Pandey, Akhilesh
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2016
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356856/
https://ncbi.nlm.nih.gov/pubmed/27902967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13579
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!